Introduction 54
The mammalian target of rapamycin (mTOR) is a protein kinase that acts 55 as a central sensor of cell growth and metabolism, and regulates neuronal 56 morphogenesis through the precise control of protein synthesis (1-3). mTOR 57 serves as a core component of two different complexes, mTORC1 (sensitive to 58 rapamycin) and mTORC2, which control distinct cellular processes. The 59 stimulation of several G-protein coupled receptors such as D1R -but not D2R-60
can trigger mTORC1 activation (4). Upon activation, mTORC1 promotes 61 protein synthesis by phosphorylating translation regulators, including p70S6K 62 and 4EBP1 (5, 6) . In addition to its control in mRNA translation, mTORC1 has 63 been described as a postsynaptic voltage sensor, controlling the excitability of 64 neurons (7). In addition, RhoA, which recently has been mechanistically 65 connected to autistic-like behaviour (with marked modifications on locomotion 66 and social skills) in mice after the deletion of the TAOK2 gene (8) and an 67 important mediator of protein recycling in mammalian cells, is connected to the 68 activity of the mTORC1 pathway (9). The second complex, mTORC2, has a 69 lower sensitivity to rapamycin and its activation results in increased 70 phosphorylation of Akt at the serine 473 site (10). It controls cell survival and 71 the dynamics of actin cytoskeleton, which among others have been implicated 72 in the structural plasticity of dendritic spines, including those in MSNs (11) (12) (13) . 73
In general, monogenic disorders associated with the mTOR signalling 74 pathway, or "mTORopathies", match the physiological complexity and 75 heterogeneity of the mTOR function. These are commonly divided into i) 76 neurodevelopmental, such as some forms of autism (14, 15) and epileptic 77 encephalopathy (16), ii) psychiatric, including schizophrenia (17) and major 78 depressive disorder (18) and iii) neurodegenerative disorders, such as 79 Alzheimer's, Parkinson's and Huntington's disease (19) (20) (21) . Many of these 80 disorders are known to have striatum malfunction as a major factor of their 81 development (22) (23) (24) (25) (26) . 82
The striatum is the gateway to the basal ganglia and receives converging 83 sensory, emotional and cognitive information via cortical and thalamic inputs. 84
These glutamatergic synapses act on two major striatal populations of medium 85 spiny neurons: the striatonigral cells (dMSNs), which give rise to the direct 86 pathway that mainly promotes motor output, and the striatopallidal neurons 87 (iMSNs; dopamine D2R/A2aR-expressing neurons), which belong to the indirect 88 pathway, conventionally classified as inhibiting motor output. 89
Given that mTOR controls the signalling associated with striatal function 90 here we deleted mTOR specifically from D1R-expressing MSNs (dMSNs) and 91 examined animals' behaviour, as well as cell physiological and morphological 92
properties. We found that the deletion of mTOR in dMSNs induces behavioural 93 impairments associated to selective Kv1.1-channel mediated changes in 94 dMSNs electrophysiological properties, the latter also noted in rapamycin-95 treated slices. Those observations also coincided with decreased density of 96 spines along distal dendrites of dMSNs. These changes were independent of 97 protein synthesis, but sensitive to the RhoA-dependent control of K + channels 98 recycling. 99 100 101
Methods and Materials 102

Animals 103
The mTOR floxed (mTOR LoxP/LoxP ) mice used in the present study were 104 described before (27) . The mTOR Δ/LoxP were obtained by crossing 105 mTOR LoxP/LoxP mice with heterozygous PGK-Cre +/mice(28) and the resulting 106 PGK-Cre -/-mTOR Δ/wt mice were crossed with mTOR LoxP/LoxP mice. The Cre-107 mediated deletion of mTOR in dMSNs was obtained by crossing Drd1-Cre 108 heterozygous mice (29) 
Western blot analysis 127
Briefly, the striata of mice were rapidly dissected and homogenized using 20 139 up-and-down strokes of a pre-chilled glass homogenizer with 800 μl of 140 polysomal buffer containing 50 mM Tris pH = 7.8, 240 mM KCl, 10 mM MgCl2, 141 250 mM D-sucrose, 2% Triton X-100, 20 μl/ml emetine, 5 mM DTT, 100 U/ml 142 RNasin (Promega) and protease inhibitor cocktail (Roche). Samples were 143 centrifuged for 5 min at 16,100 × g at 4 • C and supernatant was incubated with 144 100 μg/ml of puromycin for 10 min at 4 • C and then boiled for 10 min at 100 • C. 145
Spontaneous locomotor activity 146
Horizontal and vertical activity was measured for a period of 120 minutes 147 in a circular corridor (Imetronic, Pessac, France) as previously described (35). 148
Counts for horizontal activity were incremented by consecutive interruption of 149 two adjacent beams placed at a height of 1 cm per 90 o sector of the corridor 150 and counts for vertical activity (rearings) as interruption of beams placed at a 151 height of 7.5 cm along the corridor (mice stretching upwards). 152
Accelerating rotarod 153
Mice were placed on a rotarod apparatus (Columbus Instruments, USA) 154 accelerating from 4 to 40 rpm in 5 min. Trials began by placing the mouse on 155 the rod and beginning rotation. Each trial ended when the mouse fell off the 156 rod, and latency was recorded. Mice were tested for four trials a day (1-min 157 inter-trial interval) for 3 consecutive days (36). 158
Elevated plus maze 159
Anxiety-like behaviour was measured as previously described (37). The 160 elevated plus maze test was performed in a black Plexiglas apparatus with four 161 arms (29 cm long, 5 cm wide) set in cross from a neutral central square (5 cm 162
x 5 cm) elevated 40 cm above the floor. 163
Marble burying test 164
Repetitive behaviour was assessed by marble burying activity. Mice 165 were placed in a clean cage (46 × 20 × 14 cm) with 4 cm sawdust bedding 166 overlayed by 20 glass marbles (15 mm diameter) equidistant in a 4 × 5 167 arrangement. Mice were allowed to explore the cage for 20 min and the number 168 of marbles buried (>50% of the marble covered by the bedding) was counted. 169
Three-chamber social approach 170
A three-chamber arena was used to assess sociability, preference for 171 social novelty, and social memory as previously (38). The discrimination index 
Brain slice preparation and Patch-clamping 177
All the procedures were similar to those described before(39). 3 months-178 old animals were used for these experiments. Coronal striatal slices were left 179 in the chamber at 34°C to recover for at least 1 h before recording. In the set of 180 experiments involving rapamycin (200 nM, Sigma-Aldrich, Germany) slices 181 were let to recover in rapamycin-infused aCSF or DMSO (control group) for 75 182 min as described before(40). In the case of anisomycin (50 μM, Sigma-Aldrich, 183
Germany) protocol, rapamycin was added to aCSF 30 min after anisomycin 184 and 75 additional min were counted. C3 exoenzyme from Clostridium 185 Botulinum (0.5 µg/ml, Cytoskeleton Inc., #CT04) was infused in aCSF for 4 h 186 before any combined treatment following instructions of the manufacturer. 187
After the recovery period, slices were placed in a submersion-type 188 chamber at room temperature with 2 ml/min rate of aCSF saturated with 95% 189 O2 and 5% CO2. Biocytin (0.5%) was added aiming 3D reconstruction of 190 patched-neurons. Access resistance, membrane resistance and membrane 191 capacitance were extracted from voltage-clamp recordings by analysing current 192 relaxation induced by a 10 mV step change from a holding potential of -80 mV 193 as described previously (41). Intrinsic excitability was investigated in current-194 clamp by setting the resting membrane potential at -80 mV and injecting 1 s 195 depolarizing steps (from 0 to 250 pA in 10 pA increments). The fast phase of 196 afterhyperpolarisation potentials (fAHP) was calculated as described (42). 197
Tetraethylammonium chloride (TEA, 50 μM, Sigma-Aldrich, Germany) and 198
Dendrotoxin-K (30 nM, Sigma-Aldrich, Germany), stromatoxin (Alomone, 199 Jerusalem, Israel) or Phrixotoxin-2 (Alomone, Jerusalem, Israel) were infused 200 into the aCSF solution and recordings performed 10 minutes after. The 201 concentration of TEA was based on a previous work of Hadley and colleagues 202 (43) . All recordings were analyzed using the IgorPro® 6.3 software 203 (Wavemetrics, PO, USA). 204
Immunohistochemistry and 3D-reconstruction 205
We used a slightly modified version of the protocol used before in our 206 laboratory (44). Slices were incubated overnight at 4°C in paraformaldehyde 207 solution (4% in 0.01 mM PBS). After fixation, slices were washed 3 times in 208 PBS and incubated in PBS-0. test. If parametric, the Student´s t-test or the analysis of variance (ANOVA) 229
followed by the Tukey test was performed. Non-parametric tests such as the 230
Mann-Whitney and Kruskal-Wallis were followed by the Dunn´s test. All tests 231
were performed using the Graph Pad Prism 6 software package (Graph Pad, 232
San Diego, CA, USA). The accepted level of significance for the tests was P ≤ 233 0.05. All descriptive statistical results are summarized in the Supplementary 234 Table 2 . (phosphorylated at threonine 37/46) ( Figure 1C ,F) were observed in the 249 striatum of D1-mTOR KO mice. In contrast, no difference was observed in the 250 phosphorylation state of Akt at serine 473 suggesting that mTORC2 activity 251 was not altered in the striatum (Figure 1D ,F). Moreover, puromycin-based 252 assay revealed that global protein synthesis was not altered in the striatum of 253 D1-mTOR KO mice ( Figure 1E ). 254
Since it has been previously described that the manipulation of upstream 255 and downstream mTOR regulators affect locomotor activity (45), we evaluated 256 the voluntary locomotor activity of D1-mTOR KO and control littermates. Our 257 results revealed that the selective deletion of mTOR in dMSNs significantly 258 impaired spontaneous locomotor behaviour ( Figure 1G ). However, to note is 259 the difference in the locomotor curves over time indicating similar locomotor 260 activity during the first 20 minutes of analysis but exponential decay kinetics in 261 mTOR-KO mice. Figure 1H shows the quantification of the total ambulation 262 during a 120 minutes session corroborating the decreased locomotion in D1-263 mTOR KO mice and reveals a decrease in vertical activity in the same group 264 when compared to control mice. This reduced locomotor activity was not 265 associated with increased anxiety levels since no alterations were observed in 266 the elevated-plus maze ( Figures 1J and K) . Finally, animals were submitted to 267 the marble burying task and we found that D1-mTOR KO buried less marbles 268 than control mice, indicating altered repetitive behaviour ( Figure 1L) . 269
Interestingly, D1-mTOR KO displayed similar motor performance as littermates 270 on the rotarod suggesting that not all repetitive motor routines were affected 271 ( Figure 1I) . 272
Next, we decided to evaluate the sociability and social novelty behaviour 273 in both groups. Results gathered from the three-chamber social apparatus 274 revealed decreased sociability in D1-mTOR KO mice in comparison to control 275 littermates ( Figure 1M ) accompanied by a reduction of the total exploration time 276 ( Figure 1N ). Social novelty might have been also impaired in D1-mTOR KO 277
given that there was a trend in the time exploring/total time ratio ( Figure 1O ) 278 and a significant decrease in the total exploration time ( Figure 1P (49). Importantly, mTOR has been shown to dampen excitability by increasing 293
Kv1.1 channel function in hippocampal neurons (7, 40) . Hence, we 294 hypothesized that some of the behavioural alterations observed in D1-mTOR 295 KO mice are caused by changes in electrophysiological properties. We 296 therefore carried out the electrophysiological characterization of dMSNs in 297 presence and absence of mTOR. First, we observed that resting membrane 298 potentials (RMP) were similar between groups (Figure 2A ). Interestingly, a 40% 299 reduction in capacitance (proportional to the cell size) was observed in dMSNs 300 lacking mTOR as compared to control dMSNs ( Figure 2B ). Our 301 electrophysiological data also identified an increase in the amplitude of the fast 302 phase of afterhyperpolarization (fAHP) ( Figure 2C ). To probe for a direct and 303 acute control by mTOR of these electrophysiological changes, we employed an 304 in vitro protocol where slices from both genotypes were submitted to an 305 incubation with the mTOR inhibitor rapamycin prior the recordings, as 306 described before (40). We first confirmed the lack of modification in the RMP in 307 the presence of rapamycin or DMSO ( Figure 2D ). Rapamycin did not affect the 308 cell capacitance either in control or mTOR-KO dMSNs ( Figure 2E ). Acute in 309 vitro exposure to rapamycin in control mice phenocopied the higher amplitude 310 of the fAHP of dMSNs in D1-mTOR KO. In contrast, rapamycin exposure had 311 no effect on the enhanced fAHPs of dMSNs in D1-mTOR KO ( Figure 2F ). We 312 also computed other active properties of dMSNs such as action potential (AP) 313 threshold, amplitude, duration, depolarization and hyperpolarization rate and 314 input-output curve (data not shown) without any differences between groups. 315
To test if this increase in the amplitude of fAHP was due to a higher 316 density/function of potassium channels in D1-mTOR KO and rapamycin-treated 317 control dMSNs we first used low concentrations of TEA (a non-selective Kv 318 channels blocker) and Dendrotoxin-K (a highly selective Kv1.1 channel 319 blocker). The concentration of 30 nM of Dendrotoxin-K was selected based on 320 the curve showed in the Figure 2G aiming a concentration with minimal effects 321 in control dMSNs but that would exhibit effects in a situation where increased 322 density or function of Kv1.1 is present. Figure 2H shows that in control D1 Cre +/-323 mTOR Δ/wt Rosa26dTomato +/-dMSNs, the rapamycin-induced increase in the 324 amplitude of fAHP is re-normalized by the non-selective blockade of Kv-325 channels and the selective blockade of Kv1.1 channels. The same analysis in 326 D1 Cre +/-mTOR Δ/LoxP Rosa26dTomato +/-KO cells indicated that the higher 327 amplitude of the fAHP is promptly reduced by TEA and Dendrotoxin-K to similar 328 level than in control dMSNs in basal conditions. The effects were similar in 329 DMSO-and rapamycin-treated mTOR-KO dMSNs confirming again the 330 absence of additive effects. To further check for additional channels that could 331 be involved in the fAHP changes, we used the in vitro rapamycin protocol in Cytoskeleton reorganization is controlled by mTOR (50) and evidence 345
indicates that mTOR-dependent actin polymerization through RhoA 346 mechanisms controls spine formation and maturation (51). Moreover, the 347 increased amplitude of the fAHP coupled with the lack of changes in somatic 348 excitability could be accounted by morphological changes in distal dendritic 349 branches (52). We therefore performed 3D reconstruction of the recorded 350 dMSNs ( Figure 3A-C) . Computation of the dendritic arborization and 351 classification in different branch levels ( Figure 3D) show that mTOR-KO dMSNs 352 are less ramified when compared to the control counterparts and that 353 rapamycin has no impact on this parameter. However, both the genetic deletion 354 of mTOR in dMSNs and the pharmacological blockade of mTOR by rapamycin 355 in control animals decreased the total number of spines in dMSNs ( Figure 3E) . We next investigated whether electrophysiological and morphological 368 changes in dMSNs provoked by the pharmacological mTOR inhibition are 369 dependent of protein synthesis. Our data show that the in vitro exposure to 370 anisomycin (a protein synthesis inhibitor) prior to the recordings did not affect 371 the rapamycin-induced enhancement of Dendrotoxin-sensitive fAHPs. Similar 372 RMP values were found in all groups ( Figure 4A ) and a decreased capacitance 373 in dMSNs from Drd1-Cre +/-mTOR Δ/LoxP Rosa26dTomato +/-( Figure 4B ) was still 374 present when compared to dMSNs from control littermates. Remarkably, the 375 increase in the amplitude of the fAHP is maintained in the presence of 376 anisomycin after pharmacological blockade or genetic deletion of mTOR 377 ( Figure 4C ). Morphological data showed that the total number of spines as well 378 as spine density far from the soma remained reduced after the pharmacological 379 blockade and the genetic deletion of mTOR in dMSNs regardless of the protein 380 synthesis inhibition ( Figures 4D and F respectively) . On the other hand, there 381 is still no impact on the proximal spine density ( Figure 4E ). The lack of protein 382 synthesis involvement in these alterations suggests alternative mechanisms 383 such as channel recycling. On the other hand, exposure to C3 exo prevented the rapamycin-induced 394 increase in the fAHP amplitude in dMSNs from control D1 Cre +/-395 mTOR Δ/wt Rosa26dTomato +/mice but did not modify the increased fAHP 396 amplitude of mTOR-KO dMSNs ( Figure 5C ). 3D reconstruction of dMSNs 397 revealed that exposure to C3 exo prevented the rapamycin-induced reduction 398 of the total spine number and distal spine density ( Figures 5D and F) in control 399 dMSNs without particular changes in the reduced levels in mTOR-KO dMSNs. 400
The proximal spine density was not impacted by C3 exo (Figure 5E ). Taken 401 together, these results show that the rapamycin effects on fAHP and dMSNs 402 morphology rely on RhoA-dependent mechanisms. 403
404
Discussion 405 406
In this study, we determined the role of mTOR in dMSNs by assessing 407 how the genetic deletion of mTOR from dMSNs affects striatal-related 408 behaviours and their neurophysiology. Our behavioural data indicate that the 409 inactivation of mTOR in dMSNs disrupts several aspects of striatal circuitry 410 physiology. Using a cell-type-specific approach, we unveiled that mTOR 411 controls, through a protein synthesis-independent mechanism, the membrane 412 density of Kv1.1 using RhoA as substrate. Moreover, the genetic deletion of 413 mTOR in dMSNs induces modifications of the dendritic complexity and distal 414 spine density, resulting in behavioural changes compatible with disrupted 415 striatal function. Additionally, we found that short-term exposure of dMSNs from 416 control mice to rapamycin, a specific mTOR inhibitor (53, 54), replicates 417 electrophysiological and morphological features found in neurons genetically 418 inactivated for mTOR. 419
Our first aim was to determine the functional consequences of the 420 selective mTOR inactivation in dMSNs. Our findings that D1R-mTOR KO mice 421 exhibit impaired social and repetitive behaviours are reminiscent of phenotypes 422 observed in several forms of idiopathic autism disorders in which aberrant 423 activity of mTOR signalling has been reported (55). However, the reduced 424 repetitive behaviours and voluntary locomotion indicate that the phenotype 425 displayed by the D1R-mTOR KO mice is also intricately linked to motor 426 dysfunctions. Sutton and Caron have previously shown that the selective 427 deletion of mTOR or Raptor (a partner of mTORC1) in D1R MSNs neurons 428 decreases locomotion in mice (56). Another mTORC1 partner, Rhes, has also 429 been implicated on the striatal control of locomotion (57) reinforcing the control 430 of locomotor activity by mTOR and downstream partners. However, the acute 431 administration of rapamycin does not impact the locomotion of mice (58) 432
suggesting that modifications after the disruption of mTOR signalling are timely 433 dependent (development included) or specific to certain brain areas or 434 neuronal types. Alternatively, the lack of cell-type selectivity (on D1 and D2 435 neurons) after rapamycin administration might be compensated by secondary 436 mechanisms stabilizing the locomotor function, which cannot be reached by the 437 D1 selective genetic deletion of mTOR. 438
The modifications in the activation of core components of the 439 translational machinery such as p-4EBP1 (59) and p-p70S6K (60) could induce 440 a set of electrophysiological alterations since mTOR controls protein synthesis 441 and cell excitability. However, global changes in protein synthesis are unlikely 442 in our animals since the puromycin incorporation assay indicated similar values 443 for both groups. Kv1.1 function is known to be controlled by mTOR in a protein-444 synthesis independent manner (40). Notably, the fAHP modifications induced 445 by both the selective dMSNs genetic deletion of mTOR and the rapamycin-446 induced pharmacological blockade were connected to the Kv1.1 activity. The 447 fAHP modifications found here are similar to those observed when PTEN, an 448 upstream regulator of the Akt/mTOR pathway is mutated. However, in this 449 report, the authors associate their results with the overexpression of calcium-450 activated potassium channels in the cortex (61). The close connection between 451 low levels of mTOR signalling in the striatum and altered potassium currents 452 has been also reported in mouse models of Huntington´s disease (HD) (62). 453
Although neuronal morphological parameters such as dendritic 454 complexity, volume of the soma and spine density are governed by diverse 455 mechanisms, both mTOR complexes are key for cytoskeletal organization and 456 function (63, 64) . Changes in mTOR signalling and spine pruning defects may 457 represent a secondary mechanism in response to an imbalance between 458 excitatory and inhibitory neurotransmission, identified in both Mecp2 mutant 459 mice and Tsc1-deficient mice (both partners of mTOR) (65-67) and also linked 460 to autism. Interestingly, the deletion of the mTOR negative regulator Tsc1 461 induces increased excitability and decreased dendritic complexity in dMSNs 462 (68). 463
RhoA control over membrane recycling of proteins, mainly receptors and 464 channels (69, 70), and more specifically in the regulation of the traffic of voltage-465 gated potassium channels has been shown before (71). Interestingly, 466
Luykennar and colleagues described in rat cerebral arteries that the inhibition 467 of RhoA leads to a concomitant loss of pyrimidines control of excitability, 468
attributed on their specific case to the Kv1.2 malfunction, paired with actin 469 disorganization (72). Still, the selective prevention of modifications exerted by 470 C3 exo has only been observed in the rapamycin protocol but not in cells from 471 D1-mTOR KO mice. Two possible explanations might account for this 472 difference. First, developmental differences where mTOR is known to be an 473 important factor (73), and second, as C3 exo provides prevention, this would 474 not be observable with any approach using KO animals since the time 475 resolution is lost. 476
Altogether, our results indicate that the selective deletion of mTOR in 477 dMSNs induces deep behavioural changes accompanied by 478 electrophysiological and morphological modifications that are dependent of an 479 over function of Kv1.1 channels regulated by RhoA. We also reinforce the 480 notion of mTOR as a valid target to striatal dysfunction and provide, with cell-481 type specificity, a mechanistic hint about the dynamic changes in MSNs 482 electrophysiology and morphology that accompany striatal disorders. 483 484 effect that is partially recapitulated by the selective blockade of Kv1.1 754 (dendrotoxin-k). A similar approach but aiming the Kv4.2 (J) and Kv4.1 and 755 4.3 showed that these channels are not involved in the mTOR-mediated 756 increase of fAHP (K) (Stromatoxin 50 nM and Phrixotoxin-2 100 nM). *p<0.05 757 when compared with the DMSO control group. # p<0.05 when compared with 758 the respective genotype rapamycin exposed cells. dMSNs after the genetic deletion of mTOR but no effect of rapamycin on this 764
parameter was noted (D). Total number of spines in dMSNs is decreased after 765 the exposure to rapamycin or the genetic deletion of mTOR (E). Proximal (<50 766 μm from the soma) spine density is not affected by rapamycin or the mTOR 767 deletion in dMSNs (F) but distal spine density (>50 μm) is impaired by both 768
conditions ( 
